You are here

  • Home
  • Archive
  • Volume 11, Issue 10
  • Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D

Citation Tools

Article menu
Clinical/translational cancer immunotherapy
Original research
Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Park J, Lee JB, Lim MC On behalf of the KGOG investigators, et al
Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
Journal for ImmunoTherapy of Cancer 2023;11:e007444. doi: 10.1136/jitc-2023-007444